Vol 46, No 4 (2015)
Prace poglądowe / Reviews
Published online: 2015-09-01
Ruxolinib in therapy if myeloproliferative neoplasms Ph(-)
DOI: 10.1016/j.achaem.2015.07.004
Acta Haematol Pol 2015;46(4):292-298.
Abstract
Ruxolitinib is the first JAK kinase inhibitor registered for the treatment of primary myelofibrosis and post-polycythaemia vera myelofibrosis and post-essential thrombocytaemia myelofibrosis. The article is a summary of current clinical data with ruxolitinib therapy both in myelofibrosis and in other Ph-negative myeloproliferative neoplasms.
Keywords: Primary myelofibrosisPolycythemia rubra veraEssential thrombocytaemiaMyeloproliferative neoplasmsRuxolitinib
